Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash & Equivalents (2016 - 2025)

BioCorRx's Cash & Equivalents history spans 16 years, with the latest figure at $287688.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 319553.33% year-over-year to $287688.0; the TTM value through Sep 2025 reached $287688.0, up 319553.33%, while the annual FY2024 figure was $88033.0, 34.97% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $287688.0 at BioCorRx, up from $111872.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.9 million in Q1 2021 and bottomed at $90.0 in Q3 2024.
  • The 5-year median for Cash & Equivalents is $101080.0 (2024), against an average of $269229.6.
  • The largest annual shift saw Cash & Equivalents crashed 99.94% in 2024 before it soared 319553.33% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $85838.0 in 2021, then dropped by 20.06% to $68615.0 in 2022, then fell by 4.94% to $65222.0 in 2023, then soared by 34.97% to $88033.0 in 2024, then soared by 226.8% to $287688.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Cash & Equivalents are $287688.0 (Q3 2025), $111872.0 (Q2 2025), and $24142.0 (Q1 2025).